Telix Pharmaceuticals is trading at $10.04, down 10.08%, after its Q3 update showed group revenue fell 1% sequentially. - Group revenue was US$245 million, up 19% year over year. - Precision Medicine revenue was essentially flat quarter over quarter, raising concern that growth momentum had paused. - Telix reaffirmed FY 2026 revenue guidance and reported a higher September exit rate, but those positives did not offset the flat-quarter concern.